Shares of Tatva Chintan Pharma Chem zoomed 17 per cent to Rs 2,488.90 on the BSE in Monday’s intraday trade after the company reported a robust set of numbers for the quarter ended September 2021 (Q2FY22), on back of higher revenue. The stock of the specialty chemicals was trading at its highest level since its listing on July 29, 2021.

• Mahindra Lifespace Launches Rs 1,900-Crore Bengaluru Project; Shares Fall 1.25%
• Stocks Under F&O Ban: Bandhan Bank
• L&T Shares Trade With Nominal Losses Despite Securing Orders 
• Daily vs Weekly SIP: Which Can Supercharge Your Portfolio to the Million-Mark?
• Rail Vikas Nigam Shares Take a Hit Despite Rs 165 Crore Order 

For Q2FY22, Tatva Chintan’s consolidated net profit jumped over nine-fold to Rs 32.41 crore as against Rs 3.56 crore in Q2FY21. Revenue from operations during the quarter more than doubled to Rs 123.62 crore from Rs 60.04 crore in the corresponding quarter of previous fiscal. The company’s, earnings before interest, tax, depreciation and amortization (ebitda) margin improved to 31.3 per cent from 13.85 per cent.